News

Vaccinex will receive a technology access fee and research funding and is eligible for milestone payments and royalties. Following the initial research phase, Vaccinex may receive certain options

Results from the 165-patient trial demonstrated that nalbuphine ER positively reduced pain intensity in a dose-dependent manner over the 12-hour study period. Positive results were also observed in

The company also announced that the drug has received orphan drug designation from the FDA for the treatment of pancreatic cancer. In the US, 32,000 patients annually are

Under the agreed upon terms Sigma-Aldrich gained access to the QuantiGene gene expression profiling assay and Genospectra’s technologies for inducible siRNA, a unique nano-particle system for delivery of

Specifically, the product showed potential to stimulate key immunologic parameters and to stabilize the loss of CD4+ cells, which could help prolong the time before these patients need

The initial license granted to Genentech allows the US biotechnology company to use the GS system only for R&D purposes. However, the agreement does provide options for Genentech

According to the report authors, there is a lack of quantifiable evidence on the costs and benefits of implementing major policies such as reducing waiting times within the

Data from Sangamo’s developmental program has shown that its zinc finger DNA-binding protein (ZFP) can be used to make cells resistant to HIV infection by permanently modifying the

Mammography and physical examination are both used to detect the possibility of breast cancer. A woman receiving an abnormal mammogram or physical examination needs further confirmation to determine